{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:42:42Z","timestamp":1792402962738,"version":"4.4.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,11,30]],"date-time":"2015-11-30T00:00:00Z","timestamp":1448841600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s40265-015-0522-7","type":"journal-article","created":{"date-parts":[[2015,11,30]],"date-time":"2015-11-30T07:22:03Z","timestamp":1448868123000},"page":"147-154","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":135,"title":["Talimogene Laherparepvec: First Global Approval"],"prefix":"10.1007","volume":"76","author":[{"given":"Sarah L.","family":"Greig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,30]]},"reference":[{"issue":"9","key":"522_CR1","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","volume":"14","author":"HL Kaufman","year":"2015","unstructured":"Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14(9):642\u201362.","journal-title":"Nat Rev Drug Discov."},{"issue":"4","key":"522_CR2","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/jso.23494","volume":"109","author":"P Hersey","year":"2014","unstructured":"Hersey P, Gallagher S. Intralesional immunotherapy for melanoma. J Surg Oncol. 2014;109(4):320\u20136.","journal-title":"J Surg Oncol."},{"key":"522_CR3","unstructured":"Amgen Inc. Imlygic\u2122 (talimogene laherparepvec) suspension for intralesional injection: US prescribing information. 2015. http:\/\/www.fda.gov\/biologicsbloodvaccines . Accessed 12 Nov 2015."},{"key":"522_CR4","unstructured":"US Food and Drug Administration. FDA approves first-of-its-kind product for the treatment of melanoma [media release]. 27 Oct 2015. http:\/\/www.fda.gov ."},{"key":"522_CR5","unstructured":"Amgen Inc. FDA approves Imlygic\u2122 (talimogene laherparepvec) as first oncolytic viral therapy in the US [media release]. 27 Oct 2015. http:\/\/www.amgen.com ."},{"key":"522_CR6","unstructured":"European Medicines Agency. CHMP summary of positive opinion for Imlygic. 2015. http:\/\/www.ema.europa.eu . Accessed 28 Oct 2015."},{"key":"522_CR7","unstructured":"Amgen Inc. Amgen completes acquisition of BioVex [media release]. 4 Mar 2011. http:\/\/www.amgen.com ."},{"key":"522_CR8","unstructured":"Amgen Inc, Merck. Amgen and Merck announce collaboration to evaluate investigational combination treatment for advanced melanoma [media release]. 5 Feb 2014. http:\/\/www.amgen.com ."},{"key":"522_CR9","unstructured":"Amgen Inc, Merck. Amgen and Merck announce expansion of collaboration to support studies of talimogene laherparepvec in combination with Keytruda\u00ae (pembrolizumab) in patients with head and neck cancer [media release]. 29 May 2015. http:\/\/www.amgen.com ."},{"key":"522_CR10","unstructured":"Amgen Inc. Amgen announces collaboration with Roche on cancer immunotherapy study with investigational medicines talimogene laherparepvec and atezolizumab [media release]. 2 June 2015. http:\/\/www.amgen.com ."},{"key":"522_CR11","unstructured":"Roche. Roche announces collaboration with Amgen on cancer immunotherapy study with investigational medicines talimogene laherparepvec and atezolizumab (MPDL3280A) [media release]. 2 June 2015. http:\/\/www.roche.com ."},{"issue":"6","key":"522_CR12","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2217\/fon.10.66","volume":"6","author":"HL Kaufman","year":"2010","unstructured":"Kaufman HL, Bines SD. OPTiM trial: a phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol. 2010;6(6):941\u20139.","journal-title":"Future Oncol."},{"key":"522_CR13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/2051-1426-2-11","volume":"2","author":"HL Kaufman","year":"2014","unstructured":"Kaufman HL, Ruby CE, Hughes T, et al. Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. J Immunother Cancer. 2014;2:11.","journal-title":"J Immunother Cancer."},{"issue":"4","key":"522_CR14","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/sj.gt.3301885","volume":"10","author":"BL Liu","year":"2003","unstructured":"Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003;10(4):292\u2013303.","journal-title":"Gene Ther."},{"key":"522_CR15","doi-asserted-by":"crossref","unstructured":"Piasecki J, Rottman J, Le T, et al. Talimogene laherparepvec activates systemic T-cell-mediated anti-tumor immunity [abstract no. 4287]. Cancer Res. 2015;75(15 Suppl).","DOI":"10.1158\/1538-7445.AM2015-4287"},{"issue":"22","key":"522_CR16","doi-asserted-by":"crossref","first-page":"6737","DOI":"10.1158\/1078-0432.CCR-06-0759","volume":"12","author":"JCC Hu","year":"2006","unstructured":"Hu JCC, Coffin RS, Davis CJ, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 2006;12(22):6737\u201347.","journal-title":"Clin Cancer Res."},{"issue":"3","key":"522_CR17","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1245\/s10434-009-0809-6","volume":"17","author":"HL Kaufman","year":"2010","unstructured":"Kaufman HL, Kim DW, Deraffele G, et al. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol. 2010;17(3):718\u201330.","journal-title":"Ann Surg Oncol."},{"issue":"34","key":"522_CR18","doi-asserted-by":"crossref","first-page":"5763","DOI":"10.1200\/JCO.2009.24.3675","volume":"27","author":"NN Senzer","year":"2009","unstructured":"Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009;27(34):5763\u201371.","journal-title":"J Clin Oncol."},{"issue":"25","key":"522_CR19","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RHI Andtbacka","year":"2015","unstructured":"Andtbacka RHI, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780\u20138.","journal-title":"J Clin Oncol."},{"key":"522_CR20","doi-asserted-by":"crossref","unstructured":"Andtbacka RHI, Collichio FA, Amatruda T, et al. Final planned overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB\/C\/IV melanoma (NCT00769704) [abstract no. P263]. J Immunother Cancer. 2014;2(Suppl 3).","DOI":"10.1186\/2051-1426-2-S3-P263"},{"key":"522_CR21","doi-asserted-by":"crossref","unstructured":"Nemunaitis JJ, Andtbacka RHI, Ross M, et al. Results of the extension trial of OPTiM, a multicenter, randomized phase 3 trial of talimogene laherparepvec (T-VEC) vs GM-CSF for unresected stage IIIb-IV melanoma [abstract no. 1102P]. Ann Oncol. 2014;25(Suppl 4):iv382.","DOI":"10.1093\/annonc\/mdu344.18"},{"issue":"15","key":"522_CR22","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1158\/1078-0432.CCR-10-0196","volume":"16","author":"KJ Harrington","year":"2010","unstructured":"Harrington KJ, Hingorani M, Tanay MA, et al. Phase I\/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III\/IV squamous cell cancer of the head and neck. Clin Cancer Res. 2010;16(15):4005\u201315.","journal-title":"Clin Cancer Res."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0522-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-015-0522-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0522-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T22:10:00Z","timestamp":1567375800000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-015-0522-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,30]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["522"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0522-7","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726133764.793522354","asserted-by":"object"}]},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,30]]}}}